NEO100
Recurrent High-Grade Glioma (e.g., Glioblastoma)
Key Facts
About NeOnc Technologies
NeOnc Technologies is a multi-Phase 2 clinical-stage biopharmaceutical company with a mission to revolutionize the treatment of brain cancers and CNS diseases by overcoming the fundamental challenge of the Blood-Brain Barrier. The company's core innovation is a proprietary intranasal delivery platform, anchored by its clinical-grade Perillyl Alcohol (POH) synthesis, which transports therapeutics directly to the brain via cranial nerve pathways. Its strategy encompasses developing proprietary drug candidates (NEO100, NEO212) while positioning its platform as an enabling technology for partnerships. Recent achievements include a strategic PIPE financing led by Cinctive Capital and the presentation of Phase 1 data for its oral NEO212 program.
View full company profile